Overview
The InterLymph Consortium, or formally the International Consortium of Investigators Working on Epidemiologic Studies of Lymphoid Malignancies, is an open scientific forum for epidemiologic research in lymphoid malignancies. Formed in 2001, the Consortium is a group of international investigators who have completed or ongoing case-control studies or contribute resources from completed or ongoing cohorts. InterLymph member investigators discuss and undertake research projects that pool data across studies or otherwise undertake collaborative research.
Funding Sources
Support for logistical needs of the Consortium is provided by NCI’s Division of Cancer Epidemiology and Genetics (DCEG), which is the intramural (in-house) research component of the Institute, and the Epidemiology and Genomics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS), which manages the epidemiology grant program for the Institute; the International Agency for Research on Cancer (IARC); and the Leukaemia Research Fund. Some investigators within the Consortium also have grant support for research projects.
Organizational Structure
InterLymph is led by a Coordinating Committee, which has a rotating membership. View list of current Coordinating Committee members.
The Consortium consists of five working groups focused on genetics, Hodgkin’s lymphoma, immunity and infection, lifestyle and environment, and pathology and survival. View a list of contacts for each of the working groups.
Objectives
Within the scope defined by its Mission, the objectives of InterLymph are to expand knowledge of lymphoma etiology and survival through:
- Supporting the development of early career researchers.
- Fostering collaborations between researchers in different countries;
- Providing a framework for the efficient conduct and publication of original data meta-analyses of relevant studies;
- Providing a forum and framework for discussion, development and pursuit of new research directions; and